Table 3.

Disease-modifying treatment (DMT) as a risk factor for severe COVID-19 outcome in multiple sclerosis patients.^a

	Univariate analysis, (n=332)		Multivariate analysis, (n=332)
DMT	OR (95% CI)	p value	OR (95% CI)	p value
Interferon	0.39 (0.17–0.81)	0.02	0.72 (0.34–1.40)	0.26
Glatiramer acetate	0.36 (0.14–0.79)	0.01	0.81 (0.42–1.83)	0.42
Teriflunomide	0.54 (0.29–1.17)	0.82	0.83 (0.39–1.97)	0.67
Fumaratesb	0.47 (0.17–0.79)	0.01	1.08 (0.49–2.09)	0.74
S1P modulatorsc	0.57 (0.21–0.96)	0.04	1.12 (0.52–2.34)	0.85
Natalizumab	0.42 (0.18–0.62)	0.01	1.18 (0.53–2.10)	0.76
Anti-CD20d	0.81 (0.63–1.23)	0.14	2.18 (1.53–4.58)	0.01
Other	0.41 (0.22–1.07)	0.07	1.24 (0.36–2.22)	0.80
No therapye	1 (ref)		1 (ref)

Abbreviations: CI, confidence interval; COVID-19, corona virus disease 2019; OR, odds ratio.

^aIntensive care unit admission, mechanical ventilation, and/or death.

^bDimethyl fumarate, diroximel fumarate, or monomethyl fumarate.

^cFingolimod, siponimod, or ozanimod.

^dOcrelizumab or rituximab.

^eThe no therapy group was used as the reference category.